Real-world study of adebrelimab as first-line therapy for extensive-stage small cell lung cancer: a retrospective study
BackgroundExtensive-stage small cell lung cancer (ES-SCLC) has a poor prognosis, with historical median overall survival (OS) of 8–13 months under platinum-etoposide chemotherapy. While phase III trials established adebrelimab (anti-PD-L1) plus chemotherapy as a new standard, real-world evidence rem...
Zapisane w:
| Główni autorzy: | , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Frontiers Media S.A.
2025-10-01
|
| Seria: | Frontiers in Immunology |
| Hasła przedmiotowe: | |
| Dostęp online: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1678020/full |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|